Sign up
Pharma Capital

BioPorto names Amy Winslow president of US subsidiary as it prepares FDA applications

Before joining BioPorto, Winslow was president and CEO of Magellan Diagnostics in Boston
Kidney diagram in a pair of hands
The NGAL Test is designed to detect acute kidney injury by measuring NAGL levels

BioPorto A/S (CPH:BIOPOR) named Amy Winslow president of its US subsidiary, BioPorto Diagnostics Inc, as it prepares FDA applications for a new kidney diagnostic test, the Denmark company announced Monday.

Before joining BioPorto, which provides diagnostic tests and antibodies to health care professionals, Winslow was president and CEO of Magellan Diagnostics, a point-of-care company based in Boston. She increased its profitability and ultimately led a sale of the company.

Prior to that, she served as VP of marketing at Athena Diagnostics, a neurodiagnostic medical laboratory.

WATCH: BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test

“I am pleased to welcome Amy to BioPorto’s leadership team,” CEO Peter Eriksen said. “As we prepare for FDA clearance of The NGAL Test, it is critical to establish a strong presence in the US to deliver rapid growth. Amy will lead this charge.”

The NGAL Test is designed to detect acute kidney injury by measuring NAGL levels, a biomarker which increases in response injury, as much as 24 hours before it would otherwise be detectable.

BioPorto expects to submit two regulatory clearance applications for the test to the FDA in 2019, one in the first half of the year for clinical use in children under 21 and one in the second half of the year for use in adults.

The Copenhagen-listed stock closed up 1.4% to 3.92 krones.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel
 

1551807154_andrew.jpg
Why Invest In BioPorto? Read More Here

Register here to be notified of future BIOPOR Company articles
View full BIOPOR profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.